身痛逐瘀汤联合唑来膦酸治疗前列腺癌骨转移疼痛40例

Shentongzhuyu Decoction Combined with Zoledronic Acid in the Treatment of 40 Cases of Prostate Cancer Patients with Pain from Bone Metastases

目的:观察身痛逐瘀汤联合唑来磷酸治疗前列腺癌骨转移疼痛的临床疗效。方法:将全部40例前列腺癌骨转移患者随机分为对照组21例,治疗组19例,对照组采用单纯唑来磷酸治疗,治疗组采用身痛逐瘀汤配合唑来磷酸治疗。治疗结束后评价两组患者的疼痛缓解评分(VAS)、卡氏评分(KPS)、血清ALP、PSA水平及不良反应发生情况。结果:治疗组患者总有效率为89.4%,对照组为57.1%,组间临床疗效比较差异具有统计学意义(P<0.05)。治疗组患者生活质量显著优于对照组,血清ALP、PSA水平均明显低于对照组,差异具有统计学意义(P<0.05),组间不良反应发生率比较差异无统计学意义(P>0.05)。结论:身痛逐瘀汤联合唑来磷酸可有效缓解前列腺癌骨转移患者疼痛症状并提高患者生活质量,值得临床推广应用。

Objective.. To evaluate the efficacy of Shentong ZhuYu Tang combined with zoledronic acid in the treatment of prostate cancer patients with Pain from bone metastases. Methods ： A total of 40 cases of prostate cancer with bone metastasis were randomly divided into two groups. The patients （19 cases） in treatment group received Shentong Zhuyu Tang combined with Zoledronic acid, while gl patients in the control group had only Zoledronic acid treatment. Evaluating of the two groups pain relief scores（VAS）, Karnofsky seores（KPS）, serum ALP.PSA levels and adverse events. Results： The degree of pain relief between the two groups, The total efficiency of 89.4% in treatment group and control group 57. 1%, Kamofsky scores in the treatment group were superior to those of the control group （P〈0.05）. Serum ALP,PSA in the treatment group decreased significantly compared to that in the control group （P〈0.01）. Adverse reactions in the two groups had no significant difference（P〉0.05）. Conclusion ： Shentong Zhuyu Tang combined zoledronic acid can effectively control prostate cancer patients with bone metastases pain and improve the quality of life of patients.